More than the sum: How vascular endothelial growth factor inhibition unlocks the full potential of immune checkpoint blockade

IF 25.5 1区医学 Q1 IMMUNOLOGY

Immunity Pub Date : 2025-04-08 DOI:10.1016/j.immuni.2025.03.009

Daniel H. Shu, Mark Yarchoan

引用次数: 0

Abstract

The combination of antiangiogenic and immune checkpoint inhibitor (ICI) treatment is active in solid tumors, but the mechanism of response remains unclear. In this issue of Immunity, Benmebarek et al. show that anti-vascular endothelial growth factor enhances ICI by reprogramming regulatory T cells into a fragile state.

查看原文本刊更多论文

超过总和：血管内皮生长因子抑制如何解锁免疫检查点封锁的全部潜力

抗血管生成和免疫检查点抑制剂（ICI）联合治疗在实体瘤中有活性，但反应机制尚不清楚。在本期《免疫》杂志中，Benmebarek等人表明，抗血管内皮生长因子通过将调节性T细胞重编程为脆弱状态来增强ICI。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunity 医学-免疫学

CiteScore

49.40

自引率

2.20%

发文量

205

审稿时长

6 months

期刊介绍： Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.